MEDICINES FOR CANCER TREATMENT
To provide pharmaceutical compositions, kits and techniques for effectively treating GPC1-positive cancers.SOLUTION: Disclosed is a medicament for treating cancer, which comprises T cells having a chimeric antigen receptor to bind glypican 1 (GPC1) as an effective ingredient, where the medicament is...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; jpn |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KAWAKAMI YUTAKA MATSUI AYUKO KATO HIROTAKA YAGUCHI TOMONORI SHOJI TORU WAKUI TSUGUNORI |
| description | To provide pharmaceutical compositions, kits and techniques for effectively treating GPC1-positive cancers.SOLUTION: Disclosed is a medicament for treating cancer, which comprises T cells having a chimeric antigen receptor to bind glypican 1 (GPC1) as an effective ingredient, where the medicament is used with concomitant administration of an immune checkpoint inhibitor according to the following regimen (a) and (b) to maintain the anti-tumor activity of the T cells: (a) an effective amount of the T cells is administered to a cancer patient; and (b) the immune checkpoint inhibitor is continuously administered in an amount of 0.01-100 mg/kg body weight every 1-5 week.SELECTED DRAWING: None
【課題】ＧＰＣ１陽性のがんを効果的に治療する医薬組成物、キット及び技術を提供する。【解決手段】グリピカン１（ＧＰＣ１）に結合するキメラ抗原受容体を有するＴ細胞を有効成分とし、下記（ａ）及び（ｂ）のレジメンで免疫チェックポイント阻害剤と共に投与することにより前記Ｔ細胞の抗腫瘍活性を維持するための、がん治療用医薬。（ａ）がん患者に前記Ｔ細胞の有効量を投与する（ｂ）前記がん患者に１回あたり０．０１ｍｇ／ｋｇ体重〜１００ｍｇ／ｋｇ体重の前記免疫チェックポイント阻害剤を、１〜５週間ごとに継続投与する【選択図】なし |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2020189835A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2020189835A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2020189835A3</originalsourceid><addsrcrecordid>eNrjZJDzdXXxdPb0cw1WcPMPUnB29HN2DVIICXJ1DPF19QvhYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBkYGhhaWFsamjsZEKQIA6YohvQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MEDICINES FOR CANCER TREATMENT</title><source>esp@cenet</source><creator>KAWAKAMI YUTAKA ; MATSUI AYUKO ; KATO HIROTAKA ; YAGUCHI TOMONORI ; SHOJI TORU ; WAKUI TSUGUNORI</creator><creatorcontrib>KAWAKAMI YUTAKA ; MATSUI AYUKO ; KATO HIROTAKA ; YAGUCHI TOMONORI ; SHOJI TORU ; WAKUI TSUGUNORI</creatorcontrib><description>To provide pharmaceutical compositions, kits and techniques for effectively treating GPC1-positive cancers.SOLUTION: Disclosed is a medicament for treating cancer, which comprises T cells having a chimeric antigen receptor to bind glypican 1 (GPC1) as an effective ingredient, where the medicament is used with concomitant administration of an immune checkpoint inhibitor according to the following regimen (a) and (b) to maintain the anti-tumor activity of the T cells: (a) an effective amount of the T cells is administered to a cancer patient; and (b) the immune checkpoint inhibitor is continuously administered in an amount of 0.01-100 mg/kg body weight every 1-5 week.SELECTED DRAWING: None
【課題】ＧＰＣ１陽性のがんを効果的に治療する医薬組成物、キット及び技術を提供する。【解決手段】グリピカン１（ＧＰＣ１）に結合するキメラ抗原受容体を有するＴ細胞を有効成分とし、下記（ａ）及び（ｂ）のレジメンで免疫チェックポイント阻害剤と共に投与することにより前記Ｔ細胞の抗腫瘍活性を維持するための、がん治療用医薬。（ａ）がん患者に前記Ｔ細胞の有効量を投与する（ｂ）前記がん患者に１回あたり０．０１ｍｇ／ｋｇ体重〜１００ｍｇ／ｋｇ体重の前記免疫チェックポイント阻害剤を、１〜５週間ごとに継続投与する【選択図】なし</description><language>eng ; jpn</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201126&DB=EPODOC&CC=JP&NR=2020189835A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20201126&DB=EPODOC&CC=JP&NR=2020189835A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KAWAKAMI YUTAKA</creatorcontrib><creatorcontrib>MATSUI AYUKO</creatorcontrib><creatorcontrib>KATO HIROTAKA</creatorcontrib><creatorcontrib>YAGUCHI TOMONORI</creatorcontrib><creatorcontrib>SHOJI TORU</creatorcontrib><creatorcontrib>WAKUI TSUGUNORI</creatorcontrib><title>MEDICINES FOR CANCER TREATMENT</title><description>To provide pharmaceutical compositions, kits and techniques for effectively treating GPC1-positive cancers.SOLUTION: Disclosed is a medicament for treating cancer, which comprises T cells having a chimeric antigen receptor to bind glypican 1 (GPC1) as an effective ingredient, where the medicament is used with concomitant administration of an immune checkpoint inhibitor according to the following regimen (a) and (b) to maintain the anti-tumor activity of the T cells: (a) an effective amount of the T cells is administered to a cancer patient; and (b) the immune checkpoint inhibitor is continuously administered in an amount of 0.01-100 mg/kg body weight every 1-5 week.SELECTED DRAWING: None
【課題】ＧＰＣ１陽性のがんを効果的に治療する医薬組成物、キット及び技術を提供する。【解決手段】グリピカン１（ＧＰＣ１）に結合するキメラ抗原受容体を有するＴ細胞を有効成分とし、下記（ａ）及び（ｂ）のレジメンで免疫チェックポイント阻害剤と共に投与することにより前記Ｔ細胞の抗腫瘍活性を維持するための、がん治療用医薬。（ａ）がん患者に前記Ｔ細胞の有効量を投与する（ｂ）前記がん患者に１回あたり０．０１ｍｇ／ｋｇ体重〜１００ｍｇ／ｋｇ体重の前記免疫チェックポイント阻害剤を、１〜５週間ごとに継続投与する【選択図】なし</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZJDzdXXxdPb0cw1WcPMPUnB29HN2DVIICXJ1DPF19QvhYWBNS8wpTuWF0twMSm6uIc4euqkF-fGpxQWJyal5qSXxXgFGBkYGhhaWFsamjsZEKQIA6YohvQ</recordid><startdate>20201126</startdate><enddate>20201126</enddate><creator>KAWAKAMI YUTAKA</creator><creator>MATSUI AYUKO</creator><creator>KATO HIROTAKA</creator><creator>YAGUCHI TOMONORI</creator><creator>SHOJI TORU</creator><creator>WAKUI TSUGUNORI</creator><scope>EVB</scope></search><sort><creationdate>20201126</creationdate><title>MEDICINES FOR CANCER TREATMENT</title><author>KAWAKAMI YUTAKA ; MATSUI AYUKO ; KATO HIROTAKA ; YAGUCHI TOMONORI ; SHOJI TORU ; WAKUI TSUGUNORI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2020189835A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KAWAKAMI YUTAKA</creatorcontrib><creatorcontrib>MATSUI AYUKO</creatorcontrib><creatorcontrib>KATO HIROTAKA</creatorcontrib><creatorcontrib>YAGUCHI TOMONORI</creatorcontrib><creatorcontrib>SHOJI TORU</creatorcontrib><creatorcontrib>WAKUI TSUGUNORI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KAWAKAMI YUTAKA</au><au>MATSUI AYUKO</au><au>KATO HIROTAKA</au><au>YAGUCHI TOMONORI</au><au>SHOJI TORU</au><au>WAKUI TSUGUNORI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MEDICINES FOR CANCER TREATMENT</title><date>2020-11-26</date><risdate>2020</risdate><abstract>To provide pharmaceutical compositions, kits and techniques for effectively treating GPC1-positive cancers.SOLUTION: Disclosed is a medicament for treating cancer, which comprises T cells having a chimeric antigen receptor to bind glypican 1 (GPC1) as an effective ingredient, where the medicament is used with concomitant administration of an immune checkpoint inhibitor according to the following regimen (a) and (b) to maintain the anti-tumor activity of the T cells: (a) an effective amount of the T cells is administered to a cancer patient; and (b) the immune checkpoint inhibitor is continuously administered in an amount of 0.01-100 mg/kg body weight every 1-5 week.SELECTED DRAWING: None
【課題】ＧＰＣ１陽性のがんを効果的に治療する医薬組成物、キット及び技術を提供する。【解決手段】グリピカン１（ＧＰＣ１）に結合するキメラ抗原受容体を有するＴ細胞を有効成分とし、下記（ａ）及び（ｂ）のレジメンで免疫チェックポイント阻害剤と共に投与することにより前記Ｔ細胞の抗腫瘍活性を維持するための、がん治療用医薬。（ａ）がん患者に前記Ｔ細胞の有効量を投与する（ｂ）前記がん患者に１回あたり０．０１ｍｇ／ｋｇ体重〜１００ｍｇ／ｋｇ体重の前記免疫チェックポイント阻害剤を、１〜５週間ごとに継続投与する【選択図】なし</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; jpn |
| recordid | cdi_epo_espacenet_JP2020189835A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | MEDICINES FOR CANCER TREATMENT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A36%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KAWAKAMI%20YUTAKA&rft.date=2020-11-26&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2020189835A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |